多維度評估識別重癥支氣管哮喘的可治療特質_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

胡群 ^1,2 , 吳雯雯 ^2,3,4 , 姬郁林 ¹ ,  王剛 ^1,4

1. ;
2. ;
3. ;
4. ;

Corresponding?author：

王剛, Email: wong-gang@126.com

Keywords：

DOI：

10.7507/1671-6205.202011034

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 胡群, 吳雯雯, 姬郁林, 王剛. 多維度評估識別重癥支氣管哮喘的可治療特質. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(4): 282-288. doi: 10.7507/1671-6205.202011034 Copy

1.	Global Initiative for Asthma. Global strategy for asthma management and prevention, 2019[EB/OL]. Available at: www.ginasthma.org.
2.	Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet, 2018, 391(10122): 783-800.
3.	O'Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax, 2015, 70(4): 376-378.
4.	Schoettler N, Strek ME. Recent advances in severe asthma: from phenotypes to personalized medicine. Chest, 2020, 157(3): 516-528.
5.	Irwin RS, Curley FJ, French CL. Difficult-to-control asthma. Contributing factors and outcome of a systematic management protocol. Chest, 1993, 103(6): 1662-1669.
6.	Clark VL, Gibson PG, Genn G, et al. Multidimensional assessment of severe asthma: a systematic review and meta-analysis. Respirology, 2017, 22(7): 1262-1275.
7.	Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet, 2010, 376(9743): 803-813.
8.	Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J, 2016, 47(2): 410-419.
9.	MacNeil J, Loves RH, Aaron SD. Addressing the misdiagnosis of asthma in adults: where does it go wrong?. Expert Rev Respir Med, 2016, 10(11): 1187-1198.
10.	沈華浩, 杜旭菲, 應頌敏. 新版中國支氣管哮喘防治指南與全球支氣管哮喘防治創議的異同. 中華結核和呼吸雜志, 2018, 41(3): 166-168.
11.	Majellano EC, Clark VL, Winter NA, et al. Approaches to the assessment of severe asthma: barriers and strategies. J Asthma Allergy, 2019, 12: 235-251.
12.	Jang AS, Lee JH, Park SW, et al. Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest, 2005, 128(3): 1140-1145.
13.	Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J, 1999, 14(4): 902-907.
14.	Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol, 2004, 113(1): 59-65.
15.	Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis, 1993, 147(4): 832-838.
16.	Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. Eur Respir J, 2014, 43(2): 343-373.
17.	Kupczyk M, Ten Brinke A, Sterk PJ, et al. Frequent exacerbators-a distinct phenotype of severe asthma. Clin Exp Allergy, 2014, 44(2): 212-221.
18.	Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J, 2015, 46(5): 1308-1321.
19.	McDonald VM, Clark VL, Cordova-Rivera L, et al. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J, 2020, 55(3): 1901509.
20.	May L, Carim M, Yadav K. Adult asthma exacerbations and environmental triggers: a retrospective review of ED visits using an electronic medical record. Am J Emerg Med, 2011, 29(9): 1074-1082.
21.	Zheng XY, Ding H, Jiang LN, et al. Association between air pollutants and asthma emergency room visits and hospital admissions in time series studies: a systematic review and meta-analysis. PLoS One, 2015, 10(9): e0138146.
22.	Bateman ED, Buhl R, O'Byrne PM, et al. Development and validation of a novel risk score for asthma exacerbations: the risk score for exacerbations. J Allergy Clin Immunol, 2015, 135(6): 1457-1464.
23.	Ramsahai JM, Hansbro PM, Wark PAB. Mechanisms and management of asthma exacerbations. Am J Respir Crit Care Med, 2019, 199(4): 423-432.
24.	Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med, 2017, 195(3): 302-313.
25.	中華醫學會呼吸病學分會哮喘學組, 中國哮喘聯盟. 重癥哮喘診斷與處理中國專家共識. 中華結核和呼吸雜志, 2017, 40(11): 813-829.
26.	Simpson JL, Phipps S, Baines KJ, et al. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J, 2014, 43(4): 1067-1076.
27.	張曉巖, 林江濤, 王文雅, 等. 35 例重癥支氣管哮喘患者臨床特征和氣道炎癥表型. 中華內科雜志, 2019, 58(9): 680-684.
28.	Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet, 2002, 360(9347): 1715-1721.
29.	Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity, 2019, 50(4): 975-991.
30.	Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med, 2019, 8(9): 1375.
31.	Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J, 2014, 44(1): 97-108.
32.	Cowan DC, Taylor DR, Peterson LE, et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol, 2015, 135(4): 877-883.
33.	Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med, 2017, 377(10): 965-976.
34.	Kalchiem-Dekel O, Yao X, Levine SJ. Meeting the challenge of identifying new treatments for type 2-low neutrophilic asthma. Chest, 2020, 157(1): 26-33.
35.	Semprini R, Shortt N, Ebmeier S, et al. Change in biomarkers of type-2 inflammation following severe exacerbations of asthma. Thorax, 2019, 74(1): 95-98.
36.	Chung KF. Diagnosis and management of severe asthma. Semin Respir Crit Care Med, 2018, 39(1): 91-99.
37.	黃茂, 吉寧飛, 吳超杰. 重癥哮喘氣道炎癥機制的新進展. 中華結核和呼吸雜志, 2017, 40(11): 810-812.
38.	Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respirology, 2017, 22(4): 651-661.
39.	楊樹升, 林麗. 36 例阿司匹林哮喘回顧性分析. 中國呼吸與危重監護雜志, 2012, 11(5): 448-451.
40.	周瑛, 肖平, 張有志, 等. 阿司匹林哮喘: 回顧性分析. 中華哮喘雜志(電子版), 2008, 2(1): 56-59.
41.	陳欣, 林江濤. 運動誘發性哮喘. 中日友好醫院學報, 2000, 14(4): 239-241.
42.	Bisaccioni C, Aun MV, Cajuela E, et al. Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis. Clinics, 2009, 64(8): 769-773.
43.	Sharma B, Sharma M, Daga MK, et al. Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux. World J Gastroenterol, 2007, 13(11): 1706-1710.
44.	Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale. an updated literature review. J Psychosom Res, 2002, 52(2): 69-77.
45.	Wood LG, Gibson PG. Dietary factors lead to innate immune activation in asthma. Pharmacol Ther, 2009, 123(1): 37-53.
46.	Rastogi D, Fraser S, Oh J, et al. Inflammation, metabolic dysregulation, and pulmonary function among obese urban adolescents with asthma. Am J Respir Crit Care Med, 2015, 191(2): 149-160.
47.	McDonald VM, Fingleton J, Agusti A, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report. Eur Respir J, 2019, 53(5): 1802058.
48.	Shrimanker R, Choo XN, Pavord ID. A new approach to the classification and management of airways diseases: identification of treatable traits. Clin Sci (Lond), 2017, 131(10): 1027-1043.
49.	Han YY, Zhang X, Wang J, et al. Multidimensional assessment of asthma identifies clinically relevant phenotype overlap: a cross-sectional study. J Allergy Clin Immunol Pract, 2021, 9(1): 349-362.
50.	Agache I. Severe asthma phenotypes and endotypes. Semin Immunol, 2019, 46: 101301.
51.	McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology, 2019, 24(1): 37-47.
52.	Simpson AJ, Hekking PP, Shaw DE, et al. Treatable traits in the European U-BIOPRED adult asthma cohorts. Allergy, 2019, 74(2): 406-411.
53.	Tay TR, Hew M. Comorbid "treatable traits" in difficult asthma: current evidence and clinical evaluation. Allergy, 2018, 73(7): 1369-1382.

1. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2019[EB/OL]. Available at: www.ginasthma.org.
2. Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet, 2018, 391(10122): 783-800.
3. O'Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax, 2015, 70(4): 376-378.
4. Schoettler N, Strek ME. Recent advances in severe asthma: from phenotypes to personalized medicine. Chest, 2020, 157(3): 516-528.
5. Irwin RS, Curley FJ, French CL. Difficult-to-control asthma. Contributing factors and outcome of a systematic management protocol. Chest, 1993, 103(6): 1662-1669.
6. Clark VL, Gibson PG, Genn G, et al. Multidimensional assessment of severe asthma: a systematic review and meta-analysis. Respirology, 2017, 22(7): 1262-1275.
7. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet, 2010, 376(9743): 803-813.
8. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J, 2016, 47(2): 410-419.
9. MacNeil J, Loves RH, Aaron SD. Addressing the misdiagnosis of asthma in adults: where does it go wrong?. Expert Rev Respir Med, 2016, 10(11): 1187-1198.
10. 沈華浩, 杜旭菲, 應頌敏. 新版中國支氣管哮喘防治指南與全球支氣管哮喘防治創議的異同. 中華結核和呼吸雜志, 2018, 41(3): 166-168.
11. Majellano EC, Clark VL, Winter NA, et al. Approaches to the assessment of severe asthma: barriers and strategies. J Asthma Allergy, 2019, 12: 235-251.
12. Jang AS, Lee JH, Park SW, et al. Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest, 2005, 128(3): 1140-1145.
13. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J, 1999, 14(4): 902-907.
14. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol, 2004, 113(1): 59-65.
15. Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis, 1993, 147(4): 832-838.
16. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. Eur Respir J, 2014, 43(2): 343-373.
17. Kupczyk M, Ten Brinke A, Sterk PJ, et al. Frequent exacerbators-a distinct phenotype of severe asthma. Clin Exp Allergy, 2014, 44(2): 212-221.
18. Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J, 2015, 46(5): 1308-1321.
19. McDonald VM, Clark VL, Cordova-Rivera L, et al. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J, 2020, 55(3): 1901509.
20. May L, Carim M, Yadav K. Adult asthma exacerbations and environmental triggers: a retrospective review of ED visits using an electronic medical record. Am J Emerg Med, 2011, 29(9): 1074-1082.
21. Zheng XY, Ding H, Jiang LN, et al. Association between air pollutants and asthma emergency room visits and hospital admissions in time series studies: a systematic review and meta-analysis. PLoS One, 2015, 10(9): e0138146.
22. Bateman ED, Buhl R, O'Byrne PM, et al. Development and validation of a novel risk score for asthma exacerbations: the risk score for exacerbations. J Allergy Clin Immunol, 2015, 135(6): 1457-1464.
23. Ramsahai JM, Hansbro PM, Wark PAB. Mechanisms and management of asthma exacerbations. Am J Respir Crit Care Med, 2019, 199(4): 423-432.
24. Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med, 2017, 195(3): 302-313.
25. 中華醫學會呼吸病學分會哮喘學組, 中國哮喘聯盟. 重癥哮喘診斷與處理中國專家共識. 中華結核和呼吸雜志, 2017, 40(11): 813-829.
26. Simpson JL, Phipps S, Baines KJ, et al. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J, 2014, 43(4): 1067-1076.
27. 張曉巖, 林江濤, 王文雅, 等. 35 例重癥支氣管哮喘患者臨床特征和氣道炎癥表型. 中華內科雜志, 2019, 58(9): 680-684.
28. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet, 2002, 360(9347): 1715-1721.
29. Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity, 2019, 50(4): 975-991.
30. Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med, 2019, 8(9): 1375.
31. Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J, 2014, 44(1): 97-108.
32. Cowan DC, Taylor DR, Peterson LE, et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol, 2015, 135(4): 877-883.
33. Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med, 2017, 377(10): 965-976.
34. Kalchiem-Dekel O, Yao X, Levine SJ. Meeting the challenge of identifying new treatments for type 2-low neutrophilic asthma. Chest, 2020, 157(1): 26-33.
35. Semprini R, Shortt N, Ebmeier S, et al. Change in biomarkers of type-2 inflammation following severe exacerbations of asthma. Thorax, 2019, 74(1): 95-98.
36. Chung KF. Diagnosis and management of severe asthma. Semin Respir Crit Care Med, 2018, 39(1): 91-99.
37. 黃茂, 吉寧飛, 吳超杰. 重癥哮喘氣道炎癥機制的新進展. 中華結核和呼吸雜志, 2017, 40(11): 810-812.
38. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respirology, 2017, 22(4): 651-661.
39. 楊樹升, 林麗. 36 例阿司匹林哮喘回顧性分析. 中國呼吸與危重監護雜志, 2012, 11(5): 448-451.
40. 周瑛, 肖平, 張有志, 等. 阿司匹林哮喘: 回顧性分析. 中華哮喘雜志(電子版), 2008, 2(1): 56-59.
41. 陳欣, 林江濤. 運動誘發性哮喘. 中日友好醫院學報, 2000, 14(4): 239-241.
42. Bisaccioni C, Aun MV, Cajuela E, et al. Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis. Clinics, 2009, 64(8): 769-773.
43. Sharma B, Sharma M, Daga MK, et al. Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux. World J Gastroenterol, 2007, 13(11): 1706-1710.
44. Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale. an updated literature review. J Psychosom Res, 2002, 52(2): 69-77.
45. Wood LG, Gibson PG. Dietary factors lead to innate immune activation in asthma. Pharmacol Ther, 2009, 123(1): 37-53.
46. Rastogi D, Fraser S, Oh J, et al. Inflammation, metabolic dysregulation, and pulmonary function among obese urban adolescents with asthma. Am J Respir Crit Care Med, 2015, 191(2): 149-160.
47. McDonald VM, Fingleton J, Agusti A, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report. Eur Respir J, 2019, 53(5): 1802058.
48. Shrimanker R, Choo XN, Pavord ID. A new approach to the classification and management of airways diseases: identification of treatable traits. Clin Sci (Lond), 2017, 131(10): 1027-1043.
49. Han YY, Zhang X, Wang J, et al. Multidimensional assessment of asthma identifies clinically relevant phenotype overlap: a cross-sectional study. J Allergy Clin Immunol Pract, 2021, 9(1): 349-362.
50. Agache I. Severe asthma phenotypes and endotypes. Semin Immunol, 2019, 46: 101301.
51. McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology, 2019, 24(1): 37-47.
52. Simpson AJ, Hekking PP, Shaw DE, et al. Treatable traits in the European U-BIOPRED adult asthma cohorts. Allergy, 2019, 74(2): 406-411.
53. Tay TR, Hew M. Comorbid "treatable traits" in difficult asthma: current evidence and clinical evaluation. Allergy, 2018, 73(7): 1369-1382.

Previous Article
LRBA 基因復合雜合突變致兒童彌漫性實質性肺疾病一例
Next Article
呼吸內鏡技術在慢性阻塞性肺疾病治療中的應用進展

Chinese Journal of Respiratory and Critical Care Medicine

多維度評估識別重癥支氣管哮喘的可治療特質

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content